血液製品業務保持穩定增長 華蘭生物(002007.SZ)一季度淨利預增40%-60%
格隆匯4月10日丨華蘭生物(002007.SZ)公佈2023年第一季度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利3.27億元–3.74億元,比上年同期上升40%-60%;扣除非經常性損益後的淨利潤盈利2.51億元–2.98億元,比上年同期上升16.16%-37.77%;基本每股收益盈利0.1795元/股–0.2051元/股。
報吿期內,預計公司業績較上年同期上升,主要原因為公司血液製品業務保持穩定增長;2023年第一季度全國多地甲型流感疫情呈現高發態勢,對流感疫苗銷售起到了促進作用,公司控股子公司華蘭生物疫苗股份有限公司2022年底庫存的部分流感疫苗在2023年第一季度實現銷售,疫苗銷量較上年同期明顯增長;同時,該部分疫苗已在2022年度報吿中全額計提減值準備,在實現銷售後,應結轉的成本與上年已計提的減值準備相抵消,對公司2023年第一季度的業績產生了積極影響。
2023年第一季度,公司預計非經常性損益金額對淨利潤影響金額約為7600萬元(2022年同期為1743.25萬元),主要系公司本期出售資產產生收益及利用閒置資金投資理財收益增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.